BeOne Medicines (ONC) Receivables (2017 - 2026)

BeOne Medicines (ONC) has 10 years of Receivables data on file, last reported at $938.0 million in Q1 2026.

• On a quarterly basis, Receivables rose 30.78% year-over-year to $938.0 million in Q1 2026; TTM through Mar 2026 was $938.0 million, a 30.78% increase from a year earlier, with the FY2025 full-year figure at $865.1 million, up 27.92% from the prior year.
• Receivables for Q1 2026 stood at $938.0 million, up from $865.1 million in the prior quarter.
• Over the last five years, Receivables for ONC reached as high as $938.0 million in Q1 2026 and fell as low as $174.9 million in Q2 2022.
• Historically, Receivables has averaged $493.3 million across 5 years, with a median of $435.3 million in 2024.
• On a YoY basis, Receivables climbed as much as 126.25% in 2022 and fell as far as 63.9% in 2022.
• Year by year, Receivables stood at $176.2 million in 2022, then surged by 104.17% to $359.8 million in 2023, then jumped by 87.98% to $676.3 million in 2024, then rose by 27.92% to $865.1 million in 2025, then grew by 8.43% to $938.0 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $938.0 million in Q1 2026, $865.1 million in Q4 2025, and $863.3 million in Q3 2025.